The annual fall meeting of AMCP Nexus 2022 will feature a keynote from one of the top physician-executives in health care, the specialty pharmaceutical pipeline, and insights for managed care stakeholders in selecting and integrating cost-effective, value-based care frameworks.
AMCP Nexus 2022, the annual fall meeting of the Academy of Managed Care Pharmacy, will convene this week in National Harbor, Maryland.
The meeting kicks off with a keynote address by former commissioner of the Baltimore City Health Department, Leana Wen, MD, MSc. Wen is the author of 2 books, Lifelines: A Doctor's Journey in the Fight for Public Health, and When Doctors Don't Listen: How to Avoid Misdiagnoses and Unneccessary Tests.
The opening proceedings will then focus on current and future trends in pharmacotherapy access and formulary management, including sessions on prescription digital therapeutics and HIV Pre-Exposure Prophylaxis (PrEP). State and federal health policy updates will also be discussed throughout the meeting, with managed care insights provided on topics such as the selection and integration of value-based payment models, prior authorization and price cost transparency, and the evolving US biosimilars landscape.
AMCP Talks also makes its return, with this year’s series of presentations centering on best practices to address health disparities. Managed care stakeholders from Humana, Takeda Pharmaceuticals, Duke-Margolis Center for Health Policy, and the National Committee for Quality Assurance will all speak during the interactive panel discussion.
Further strategies to improve ongoing gaps in health care, particularly the utility of shared decision-making and patient engagement, will be featured during several sessions on Thursday:
Along with the regular session, “Specialty Pharmaceuticals in Development,” from Aimee Tharaldson, PharmD, of Express Scripts, the last panel discussion on the final day of the meeting will provide an oncology-specific update on therapeutics, newly approved or currently in late-stage development, for solid and hematologic malignancies.
Bhavesh Shah, RPh, BCOP, chief pharmacy officer for Specialty and Hematology Pharmacy at Boston Medical Center (BMC), will lead the session, “Oncology Pipeline 2022: Spotlight on Trends and Agents To Watch,” with Kaelyn Boss, PharmD, clinical consultant pharmacist, Commonwealth Medicine University of Massachusetts Medical School, with added insight provided on the impact these drugs will have on current standard of care and benefit formularies in cancer care.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
2 Commerce Drive
Cranbury, NJ 08512